Actively Recruiting
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Led by University of Roma La Sapienza · Updated on 2025-04-03
60
Participants Needed
1
Research Sites
276 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
CONDITIONS
Official Title
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven locally advanced or metastatic pulmonary or gastro-entero-pancreatic neuroendocrine neoplasms eligible for first line medical therapy
- Patients with other non-malignant endocrine diseases such as benign thyroid dysfunction (control group)
You will not qualify if you...
- Severe chronic kidney disease (stage 4-5)
- Clinical or laboratory signs of significant respiratory, cardiological, or hepatobiliary disease
- Presence of other non-neuroendocrine malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Andrea M Isidori
Rome, Italy, Italy, 00161
Actively Recruiting
Research Team
A
Andrea M Isidori, MD, PhD
CONTACT
E
Elisa M Giannetta, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here